Martin Babler, Alumis CEO

Alu­mis files for IPO ahead of Phase 3 stud­ies for sec­ond-gen TYK2 in­hibitor

Pre­ci­sion im­munol­o­gy start­up Alu­mis has filed to go pub­lic, pitch­ing it­self to Wall Street just three months af­ter rais­ing $259 mil­lion from pri­vate in­vestors. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.